MetLife (MET) Q1 2026 Earnings Transcript

MetLife reported adjusted earnings of $1.6 billion, up 18% year over year, with adjusted EPS rising 23% to $2.42 and ROE reaching 17%, the top end of its target range. Broad-based revenue growth, a 11.9% direct expense ratio, and strong capital returns of $1.1 billion in buybacks/dividends support the upbeat result, though RIS spreads edged down 4 bps sequentially and Latin America saw some tax-related pressure. Management also highlighted $518 million of variable investment income, continued AI/technology investment, and strong balance sheet metrics including $3.9 billion of holding company liquidity and a 379% NAIC RBC ratio.

Analysis

MET is not just printing a clean quarter; it is showing that the strategy is creating a self-reinforcing loop between capital intensity and earnings quality. The key second-order read is that management is using excess capital generation from underwriting and investment income to buy back stock while still keeping liquidity and RBC comfortably above targets, which should lower equity risk premium over time if sustained. That combination usually supports multiple expansion in insurers, especially when it comes with evidence that expense inflation is being absorbed rather than passed through to customers.

The most interesting subtlety is that the current earnings mix still has some duration risk masked by elevated private-market income. VII has now helped three quarters in a row, but that is exactly the kind of line item that can flatten EPS volatility until market marks or exit activity normalize; if private equity and venture returns cool, reported growth will decelerate faster than operating momentum. On the other hand, the business is increasingly positioned to benefit from a prolonged flat-to-slightly-steepening curve through spread capture in retirement and reinsurance, so the medium-term setup is more about liability origination than rate beta.

The clearest underappreciated bull case is that MET is becoming a consolidator in non-medical benefits, retirement reinsurance, and investment management distribution, with AI used less as a buzzword and more as an operating expense suppressant. That creates a moat against smaller peers that cannot match its capital flexibility or distribution breadth. The main risk is that investors over-assign durability to favorable mortality, VII, and tax tailwinds; if any two of those revert simultaneously, the market may re-rate the stock back to a lower-quality insurer multiple even if headline EPS stays positive.

Key Decisions for Investors

• Go long MET on weakness over the next 2-4 weeks; the setup favors a gradual re-rating if buybacks continue and management holds the 2026 targets. Use a pullback entry rather than chasing after the print; upside is driven by multiple expansion more than near-term estimate revisions.
• Pair trade: long MET / short a lower-quality life insurer with weaker capital flexibility and less diversified fee/asset-management earnings. The thesis is that MET’s mix of capital returns + diversified earnings should outperform if the market remains open to financials exposure.
• Buy MET Jan-2027 call spreads to express upside with limited premium burn; this is a cleaner way to monetize the possibility that EPS holds while the market starts rewarding capital return durability. Favor strikes near a modest re-rating rather than aggressive far-OTM structures.
• Trim or hedge MET after any rally that prices in sustained VII above normalized levels; if private equity marks roll over, consensus earnings estimates are likely too sticky and the stock could mean-revert within 1-2 quarters.
• Watch for relative long vs. asset-light financials with strong capital return but weaker operating leverage; if rates stay flat, MET’s spread origination and capital deployment should outperform names that rely more heavily on transaction-sensitive fee growth.